Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
| Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free ... (Centre Daily Times) |
|
|
|
Genentech, Inc. (NYSE:DNA) today announced that a Phase III study (ATLAS) of Tarceva® (erlotinib) in combination with Avastin® (bevacizumab) as maintenance therapy following initial treatment with Avastin plus chemotherapy in advanced non-small cell lung cancer (NSCLC) met its primary endpoint. The study was stopped early on the recommendation of an independent data safety monitoring board after ... |
Professional dialysis recruitment

